McMahon G - Search Results

1

Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders.

LaVallee TM, Alvarado D, Garton AJ, Trombetta ES, Gedrich R, McMahon G. LaVallee TM, et al. Among authors: mcmahon g. Crit Rev Oncog. 2015;20(5-6):485-508. doi: 10.1615/CritRevOncog.v20.i5-6.170. Crit Rev Oncog. 2015. PMID: 27279243 Review.

2

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.

London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R. London CA, et al. Among authors: mcmahon g. Clin Cancer Res. 2017 May 15;23(10):2565-2574. doi: 10.1158/1078-0432.CCR-16-2152. Epub 2016 Nov 4. Clin Cancer Res. 2017. PMID: 27815356 Free PMC article.

3

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.

Alvarado D, Ligon GF, Lillquist JS, Seibel SB, Wallweber G, Neumeister VM, Rimm DL, McMahon G, LaVallee TM. Alvarado D, et al. Among authors: mcmahon g. PLoS One. 2017 Jul 19;12(7):e0181356. doi: 10.1371/journal.pone.0181356. eCollection 2017. PLoS One. 2017. PMID: 28723928 Free PMC article.

4

Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.

Yang Y, Mandiyan S, Robinson BS, McMahon G. Yang Y, et al. Among authors: mcmahon g. Cancer Res. 2016 Oct 1;76(19):5788-5797. doi: 10.1158/0008-5472.CAN-16-0026. Epub 2016 Aug 22. Cancer Res. 2016. PMID: 27550450

5

Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.

London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM. London CA, et al. Among authors: mcmahon g. Clin Cancer Res. 2003 Jul;9(7):2755-68. Clin Cancer Res. 2003. PMID: 12855656 Clinical Trial.

6

VEGF receptor signaling in tumor angiogenesis.

McMahon G. McMahon G. Oncologist. 2000;5 Suppl 1:3-10. doi: 10.1634/theoncologist.5-suppl_1-3. Oncologist. 2000. PMID: 10804084 Free article. Review.

7

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.

Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA. Liao AT, et al. Among authors: mcmahon g. Blood. 2002 Jul 15;100(2):585-93. doi: 10.1182/blood-2001-12-0350. Blood. 2002. PMID: 12091352 Free article.

8

Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.

Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J. Mohammadi M, et al. Among authors: mcmahon g. Science. 1997 May 9;276(5314):955-60. doi: 10.1126/science.276.5314.955. Science. 1997. PMID: 9139660

9

Development of the first generation c-met kinase inhibitors: beginning of a path to a new treatment for cancer.

Wang X, McMahon G, Lipson KE. Wang X, et al. Among authors: mcmahon g. Mol Cancer Ther. 2011 Nov;10(11):2022-3. doi: 10.1158/1535-7163.MCT-11-0714. Mol Cancer Ther. 2011. PMID: 22072807 No abstract available.

10

Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.

Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T, Harris D, Sun L, Rice A, Vasile S, Blake RA, Howlett AR, Patel N, McMahon G, Lipson KE. Wang X, et al. Among authors: mcmahon g. Mol Cancer Ther. 2003 Nov;2(11):1085-92. Mol Cancer Ther. 2003. PMID: 14617781

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

535 results

Search Page